Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer

Menopause

Volumn 15, Issue SUPPL. 4, 2008, Pages 797-803

  Ganz, Patricia A ^a,b   Land, Stephanie R ^c,d  

^a Laboratory Medicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NSABP Foundation Inc   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Breast cancer; Postmenopausal women; Quality of life; Selective estrogen receptor modulator therapy

Indexed keywords

PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CATARACT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; FEMALE; FRACTURE; HIGH RISK POPULATION; HUMAN; LUNG EMBOLISM; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; UTERUS CANCER; VAGINA DISCHARGE; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; BREAST TUMOR; RISK ASSESSMENT; RISK FACTOR;

BREAST NEOPLASMS; FEMALE; HUMANS; POSTMENOPAUSE; QUALITY OF LIFE; RALOXIFENE; RISK ASSESSMENT; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 58149333893     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31817be9af     Document Type: Review

References (34)

1. Love RR, Philips J. Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst 2002;94:1433/1434.
2. Fabian CJ, Kimler BF. Chemoprevention of breast cancer: implications for postmenopausal women. Drugs Aging 2002;19:43/78.
3. Powles TJ, Jones AL, Ashley SE, et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 1994; 31:73/82.
4. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98/101.
5. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371/1388.
6. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93/97.
7. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002;360:817/824.
8. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189/2197.
9. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282: 637/645.
10. Ganz PA, Day R, Ware JE Jr, Redmond C, Fisher B. Base-line quality-oflife assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. J Natl Cancer Inst 1995;87: 1372/1382.
11. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol 1999;17:2659/2669.
12. Fallowfield L, Fleissig A, Edwards R, et al. Tamoxifen for the prevention of breast cancer: psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 2001;19:1885/1892.
13. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006;295:2742/2751.
14. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006;295:2727/2741.
15. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 2005;97: 1652/1662.
16. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 2007;99:283/290.
17. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95: 160/165.
18. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 2007;99:727/737.
19. Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancerV96-month follow-up of the randomized IBIS-I Trial. J Natl Cancer Inst 2007;99:272/282.
20. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125/134.
21. Day R, Ganz PA, Costantino JP. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. J Natl Cancer Inst2001;93:1615/1623.
22. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med1989;320:479/484.
23. Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998;16:501/514.
24. Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res 1998;152:396/411.
25. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296/300.
26. Decensi A, Maisonneuve P, Rotmensz N, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005;111:650/656.
27. Goldhaber SZ. Tamoxifen: preventing breast cancer and placing the risk of deep vein thrombosis in perspective. Circulation 2005;111: 539/541.
28. Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:59/69.
29. Bruner DW. Should patient-reported outcomes be mandatory for toxicity reporting in cancer clinical trials? J Clin Oncol 2007;25:5345/5347.
30. Ganz PA, Day R, Costantino J. Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. Stat Med 1998;17:613/622.
31. Thirlaway K, Fallowfield L, Cuzick J. The Sexual Activity Questionnaire: a measure of women's sexual functioning [published erratum appears in Qual Life Res 1997;6:606]. Qual Life Res 1996;5:81/90.
32. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst1999;91:1829/1846.
33. Chlebowski RT, Col N, Winer EP, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol 2002;20:3328/3343.
34. Fabian C. Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices counterpoint. Cancer Epidemiol Biomark Prev 2007;16:2210/2212.